108 results about "Intestine disorder" patented technology

There are provided novel synthetic stool preparations comprising bacteria isolated from a fecal sample from a healthy donor. The synthetic stool preparations are used for treating disorders of the gastrointestinal tract, including dysbiosis, Clostridium difficile infection and recurrent Clostridium difficile infection, prevention of recurrence of Clostridium difficile infection, treatment of Crohn's disease, ulcerative colitis, irritable bowel syndrome, inflammatory bowel disease, and diverticular disease, and treatment of food poisoning such as salmonella. Methods of preparation and methods of use of the synthetic stool preparations are also provided.

Provided herein are compositions and formulations suitable for the treatment of gastrointestinal disorders. Also provided are methods for treating, preventing, or alleviating disorders of the gastrointestinal tract, for example, those involving the esophagus.

The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition, including Crohn's disease and ulcerative colitis, and cancer.

The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition including Crohn's disease and ulcerative colitis, and cancer.

Provided herein are compositions suitable for the delivery of therapeutic agents to the gastrointestinal tract. Also provided herein are methods for treating, preventing or alleviating disorders of the gastrointestinal tract, for example, those involving the esophagus, by orally administering compositions described herein.

A small implantable stimulator(s) having at least two electrodes is implanted adjacent to a gastrointestinal nerve and / or muscle for the stimulation treatment of gastrointestinal disorders, including gastrointestinal motility, sphincteric disorders, and / or eating disorders. The stimulator provides a means of stimulating tissue at a stimulation site when desired, and may be implanted via a minimal surgical procedure.

The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition including Crohn's disease and ulcerative colitis, and cancer.

This document provides materials and methods related to bacterial compositions containing at least one bacterial organism having tryptophan decarboxylase activity. For example, bacterial compositions containing at least one bacterial organism having tryptophan decarboxylase activity and methods for using such bacterial compositions to improve gastrointestinal epithelial function and / or to treat gastrointestinal disorders are provided.

Prodrug compounds which metabolize into 5-ASA or analogs thereof, and taurine or analogs thereof, in the colon site are disclosed. Pharmaceutical compositions including the compounds, and methods of treatment using the compounds, are also disclosed. Such compounds have utility for treating or preventing gastrointestinal disorders, including colon cancer, ulcerative colitis and Crohn's disease.

The invention discloses a veterinary drug for preventing livestock bowel diseases, a preparation method of the drug, and feed. The veterinary drug contains active ingredients which are prepared from purslane, humifuse euphorbia herb, plantain herb, acalypha australis and liquorice. The veterinary drug provided by the invention has the effects of clearing away heat and toxic materials, eliminating dampness to stop dysentery and astringing to stop bleeding, can be effectively used for preventing the livestock bowel diseases such as swine transmissible gastroenteritis, piglet diarrhea, swine dysentery, chicken salmonellosis, chicken colibacillosis and chicken stphyoococcl disease, and has the advantages of an extensive material source, safety, environment-friendliness, a simple preparation process, low production cost and the like.

Provided is an application of natural faeces flora transplanting in intestinal disease treatment. Faeces of healthy people screened through multiple conditions is collected, intestinal canal mixed probiotic flora is collected through the steps of homogenating, suspending, diluting, filtering, centrifuging and the like and transplanted in the ways of a gastroscope, an enteroscope, a nose-jejunum tube, a fistulization opening, clysis and the like, flora balance in the intestinal canal is restored, and the effect of treating intestinal diseases is achieved. A method for treating bacteria with bacteria is adopted, the stability of the intestinal flora of a human body is maintained, a microecological treating method free of drug resistance and toxic and side effects is achieved, treatment is carried out in the mode of faeces bacterium capsules or bacterium liquid, and a good treatment effect is achieved on diarrhea, clostridium difficile infection, Crohn's diseases and the like.

The invention discloses an application of an SIRT1 inhibitor in the prevention and treatment of radiation-induced enteric diseases, and concretely discloses a use of the SIRT1 inhibitor in the preparation of medicines, a medicinal composition for preventing or treating radiation-induced intestinal injury, and a method for treating or preventing the radiation-induced intestinal injury. Radiation-induced intestinal epithelial injury can effectively be prevented or treated, and the survival rate of animals is significantly improved, so the problem of lack of ideal therapeutic medicines and effective treatment methods for the radiation-induced intestinal injury is effectively solved.

Provided is application of transplantation of artificially-cultured fecal floras in treatment of intestinal diseases. According to the application, feces of healthy persons screened out under various conditions is collected, and intestinal mixed probiotic floras are collected through the steps of homogenization, suspension, dilution, filtration, centrifugation and the like; culture is performed under the anaerobic condition and the aerobic condition by the adoption of a plate isolation technology, and culturable intestinal probiotic floras are picked out; transplantation of the artificially-cultured intestinal floras is performed by the means of a gastroscope, an enteroscope, a nose-jejunum tube, fistulation, clysis and the like, intestinal flora balance is recovered, and then the effect of treating intestinal diseases is achieved. Particularly, the application has a good treatment effect on diarrhea, clostridium diffieile infection, Crohn's diseases and the like.

The invention relates to a traditional Chinese medicinal composition for treating gastrointestinal tract, in particular to a medicinal composition for treating gastrointestinal tract diseases such as acute and chronic gastritis, enteritis, gastric ulcer, superficial gastritis, gastric acid, gastrectasia, indigestion and the like. The invention also relates to a preparation of the medicinal composition. The traditional Chinese medicinal composition for treating gastrointestinal tract comprises the medicaments in percentage by weight: 10-25 parts of red ginseng, 10-23 parts of poria, 8-20 parts of bighead atractylodes rhizome, 10-25 parts of rhizoma ligustici wallichii, 10-25 parts of rhizoma atractylodis, 10-25 parts of cyperus rotundus, 10-25 parts of medicated leaven, 10-25 parts of gardenia, 10-23 parts of betelnut, 8-20 parts of radix aucklandiae, 5-15 parts of liquorice, 5-8 parts of malt and 10-25 parts of hawthorn. The medicinal composition for treating the gastrointestinal tract is orally taken and has the efficacies of regulating the flow of qi, comforting the stomach, diminishing inflammation, killing pain, repairing gastrointestinal mucosa and ulceration, enhancing gastrointestinal motility, adjusting gastric acid secretion, promoting digestive absorption and the like.

Methods of determining gastro-intestinal conditions by performing a succession of breath tests or others tests, particularly for determining the gastric emptying or gastric accomodation condition of a subject. Methods of performing successive gastric emptying tests with different test meals are also presented, enabling the gastric accommodation to be determined. The effects of different test means on the results is presented. Novel substrates for use in such tests are suggested, including the use of micro-encapsulation. Breath tests for the detection of bacterial overgrowth, lactose intolerance and combinations thereof are presented.

The invention relates to an injection for treating animal diarrhoea which is prepared from green chiretta extract, methanesulfonic acid pefloxacin, auxiliary solvent, anti-oxidant, benzyl alcohol and water for injection.

The present invention relates to novel conformationally-defined macrocyclic compounds that bind to and / or are functional modulators of the motilin receptor including subtypes, isoforms and / or variants thereof. These macrocyclic compounds are useful as therapeutics for a range of gastrointestinal disorders, in particular those in which suppression or inhibition of the migrating motor complex (MMC) is effective or malfunction of gastric motility or increased motilin secretion is observed, such as hypermotilinemia, imitable bowel syndrome, dyspepsia, including gallbladder dyspepsia, diarrhea, cancer treatment-related diarrhea, cancer-induced diarrhea, chemotherapy-induced diarrhea, radiation enteritis, radiation-induced diarrhea, stress-induced diarrhea, chronic diarrhea, AIDS-related diarrhea, C. difficile associated diarrhea, traveller's diarrhea, acute infectious diarrhea, diarrhea induced by graph versus host disease, other types of diarrhea, functional gastrointestinal disorders, chemotherapy-induced nausea and vomiting (emesis), post-operative nausea and vomiting, cyclic vomiting syndrome and functional vomiting. Accordingly, methods of treating such disorders with such macrocyclic compounds and pharmaceutical compositions thereof are also provided in addition to methods of modulating the migrating motor complex.

Disclosed is a prebiotic composition comprising a combination of 2′fucosyllactose (2′FL) and isomaltooligosaccharide (IMO). The 2′FL and IMO are present in the prebiotic composition in a weight ratio of from 1:1 to 1:10. The prebiotic composition is effective for use in methods of preventing and / or treating a gastrointestinal (GI) condition in an animal, such as irritable bowel syndrome (IBS), inflammatory bowel disease(s) (IBD), Crohn's disease, and ulcerative colitis (UC). A foodstuff or beverage, a medical food, a nutritional composition, and a kit presentation, each including the prebiotic composition, and each suitable for use in methods of reducing or suppressing inflammation in an animalian tract, are also disclosed. A method of using the prebiotic composition to prevent and / or treat a GI condition in an animal is further disclosed. The method comprises administering the prebiotic composition to the animal.

The invention relates to a traditional Chinese medicine composition for treating dysentery and haemorrhoids and a preparation method. The composition is characterized by having the functions of clearing away heat and toxic materials, stopping bleeding and preventing inflammations, stopping dysentery and relieving pains, purging gut and relaxing the bowels, inducing diuresis and reducing edema, dispelling wind and removing obstruction in the meridians and the like. The matrix is prepared from the traditional Chinese medicine compositions according to weight part and an excipient in the pharmaceutical sense: scutellaria baicalensis, amaranthus spinosus, angelica sinensis, verbena, long stephania herb, eclipta alba, divaricate saposhnikovia roots, immature bitter oranges and the like. The traditional Chinese medicine composition provided by the invention can relax the bowels and stop dysentery with two-ways regulation. The traditional Chinese medicine composition has the effect of safe, wide and convenient general treatment on intestinal disease such as dysentery and haemorrhoids. At present, in the 6 cases of patients with haemorrhoids are treated by the composition, the youngest patient is 12 years old, the oldest is 55 years old, and the longest course of disease is 13 years. All the patients are cured. In 22 cases of patients with dysentery, the patients are cured in half a day in the fastest manner, and the patients are cured in the lowest manner in three days. In 7 cases of patients with constipation, defecation is completed by delivering the composition once.

The invention discloses application of carboxyl aminotriazole or pharmaceutically acceptable salts of the carboxyl aminotriazole in the preparation of medicaments for preventing and / or treating neurodegenerative diseases, amyotrophic lateral sclerosis and inflammatory bowel diseases and also relates to the medicament packages or kits comprising the medicaments.

The invention discloses a traditional Chinese medicine composition for preventing or / and treating gastrointestinal diseases and a preparation method of the composition. The traditional Chinese medicine composition comprises herba taraxaci, mix-fried licorice, fructus citri sarcodactylis, fructus crataegi, and fructus alpiniae galangae. The traditional Chinese medicine composition for preventing or / and treating gastrointestinal diseases can be prepared into any one commonly used preparation for oral administration, is obvious in curative effect on treating and preventing gastrointestinal diseases, the total efficiency on the gastrointestinal diseases can achieve more than 100%, the healing effect is good and the gastrointestinal diseases do not reoccur after being continuously tracked and observed, by utilizing the mutual synergistic effect of the active pharmaceutical ingredients in various Chinese herbal medicines, the traditional Chinese medicine composition for preventing or / and treating gastrointestinal diseases can effectively relieve the tremendous pain of people brought by diseases, is free from any toxic and side effects, short in medication treatment course, fast to effect and free from reoccurrence, thus achieving the radical treatment purpose.

The invention discloses a sulfonamide compound with tetrahydroquinoline as a core and a preparation method and application of the sulfonamide compound. The sulfonamide compound with tetrahydroquinoline as the core is novel in structure and simple in preparation method, is capable of reducing mature secretion of interleukin IL-1beta by specifically inhibiting activation of NLRP3 inflammasome, thenalleviating inflammatory injury and improving inflammatory microenvironments, has remarkable anti-inflammation activity, and meanwhile has no conspicuous toxicity for THP-1 cells. The compound disclosed by the invention can be prepared as an anti-inflammation medicine for treating inflammation related diseases, including purpurin-related periodic syndromes, inflammatory intestine problems, chronicretardant lung diseases, diabetes, rheumatic arthritis, rheumatoid arthritis, gout, non-alcoholic fatty liver diseases, chronic kidney diseases, atherosclerosis, neurodegenerative diseases and the like.

The invention belongs to the technical field of health-care foods, and particularly relates to a galactooligosaccharide prebiotic composition for treating or preventing gastrointestinal tract diseases. The galactooligosaccharide prebiotic composition for treating or preventing gastrointestinal tract diseases provided by the invention comprises the following components in parts by weight of 35-70 parts of galactooligosaccharide, 5-20 parts of fructo-oligosaccharide, 2-8 parts of a traditional Chinese medicine extract, 3-6 parts of probiotics and 2-6 parts of an intestinal tract adjusting agent.The galactooligosaccharide prebiotic composition provided by the invention can loosen bowel to relieve constipation, prevent constipation and intestinal tract diseases, comprehensively adjust digestive tract flora, promote growth of beneficial bacteria, accelerate intestinal peristalsis, reduce generation of flatulence, enhance immunity and promote cell viability, and has favorable application prospects.

A veterinary pharmaceutical composition for treating diseases of the gastrointestinal tract and intoxications of diverse etiology in animals comprises, as the active component, hydrolyzed lignin and a prebiotic from the following group: lactulose, fructooligo-saccharides, galacto-saccharides and inulin, and is in a form suitable for use in the composition of a mixture with combined feed, with a lignin content of from 30 to 95% by mass, in the form of powder of granules. The method for the prophylaxis and treatment of intoxication of diverse etiology, including mycotoxicoses, in animals, including birds, envisages that the animal will receive the above-mentioned veterinary pharmaceutical composition mixed with feed in a dosage of from 2 to 4.5 kg of the preparation per ton of combined feed, proportional to the content of mycotoxins in the combined feed. The method for the prophylaxis and treatment of diseases of the gastrointestinal tract, including dyspepsia, gastroenteritis, enteritis, colitis, hepatitis, and hepato-dystrophy, including in a toxic form, in animals, including cattle and pigs, envisages that the animal will receive the veterinary pharmaceutical composition according to claim 1 30±10 minutes prior to feeding, perorally individually or in a group method with water for watering or with the feed, 1 to 2 times per day in a dosage of from 0.2 to 0.3 g / kg of the mass of the animal. This ensures an increase in the effectiveness of the treatment and elimination of the above-mentioned defects in the use of hydrolyzed lignin, activated carbon and other generally known sorbents. At the same time, the joint use of lignin with a prebiotic as a means for the prophylaxis and treatment of animals makes it possible to produce a result in the form of a set of positive effects: minimization of side effects from the use of a sorbent; restoration of homeostasis in the gastrointestinal tract; and normalization of the metabolism indices, this finally resulting in a qualitative increase in the zootechnical and economic indices of animal husbandry.

Provided herein are methods, compositions, and kits for the treatment of an enteric nervous system disorder. Such methods may comprise administering to a subject an effective amount of a phenothiazine compound, a peripherally restricted dopamine decarboxylase inhibitor, and / or a peripherally restricted dopamine D2 receptor antagonist that does not substantially inhibit hERG channels.

The pharmaceutical composition is a combination of hydrolytic lignin with moisture of 55% to 65% consisting of the particles measuring 0.15 mm to 0.55 mm, a 45% to 55% aqueous lactulose solution, and a 50% to 55% aqueous oligosaccharide solution at the following ingredient ratio (weight percent): an aqueous lactulose solution: 10÷60; oligosaccharides: 10÷50; hydrolytic lignin: quantity sufficient. Hydrolytic lignin, lactulose and fructose oligosaccharides are sequentially added and mixed using a rotor blender. The composition is administered orally for no less than 14 days and no more than 30 days, two to four times a day, depending on the patient's weight and age. The composition is used as a medicine for treatment of the gastrointestinal disorders, including bacterial, viral, protozoal enteric infections, food poisoning, acute and chronic hepatitis and cirrhosis, diarrhea, peptic ulcer, Crohn's disease, ulcerative colitis, irritable bowel syndrome, mineral disorders with Ca / Mg deficiency, including osteoporosis and other alterations of the bone formation, as an immunomodulator in atopic dermatitis and immunodeficiency conditions, for protection and recovery of intestinal flora after antibiotic therapy, chemotherapy, and radiotherapy. The result is accelerated achievement of the effect and the enhanced action on the state of intestinal microbiocenosis as well as increased effectiveness of treatment of hepatitis and liver cirrhosis, elimination of undesired adverse effects in clinical usage, and extension of indications, i.e. the extended spectrum of usage in prevention and treatment.

The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition including Crohn's disease and ulcerative colitis, and cancer.

The invention belongs to the technical field of veterinary medicines and discloses application of coptis chinensis, amur cork-tree bark, Chinese rhubarb and skullcap dysentery inhibiting particles to preparation of medicines for treating intestinal diseases of poultry, and a medicinal composition formed by compounding the particles. The medicinal composition is formed by compounding the particles and chemical synthetic medicines for treating intestinal diseases of the poultry in a weight ratio of 200:1-5:1. When the particles and the chemical synthetic medicines for treating intestinal diseases of the poultry are compounded, the using amount of chemical synthetic medicines can be effectively reduced, the recovery time of the poultry with intestinal diseases is shortened, and an effect of treating the poultry with intestinal diseases is enhanced.